This household name may already be in your medicine cabinet..... Bayer. Now, they will be partnering with another company in Owensboro.... Kentucky bioprocessing. This partnership and Kentuckys signature crop, tobacco, make Owensboro the number one place to explore plant-based pharmaceuticals. Chief Operating Officer Barry Bratcher and chemist Steve Hume agree Owensboro is becoming the center of the plant-base pharmaceutical world. "If youre going to make a product using plant based pharmaceuticals, youre going to be coming to Owensboro, its the only place like it in the world." "Well have a biotech cluster here the core is already here i hope this will bring in more we have a chance to do something thats really top notch here in Owensboro." Hume says when Bayer comes and incorporates its magnicon technology with k-b-ps geneware technology, theyll save lives. Kbp is working on an hpv vaccine and Bayer is exploring a drug for non-hodgkins lymphoma. Chairman Hugh Hayden explains why Bayer representatives are saying kbp was the clear choice for a partnership of this magnitude. "Rather that go out and spend tremendous amounts of money to replicate the facility and expericene they will come here and take advantage of what were able to offer, thats quite a compliment." The two technologies are extremely similar--so, in teaming up, the two will use tobacco to make drugs (good drugs) On a bigger scale than anywhere else in the world. "Im really excited for Bayer, its one big pharmaceutical company that will make a way for us to make drugs everyday, mainstream drugs everyday." Hume says he sees this partnership helping companies make the process of creating a drug faster and more cost effective. Making the process less expensive will make room for creating specialty drugs for less common diseases. Kentucky bioprocessing is also expanding its research facilities to a new downtown development called Carnegie Village. They plan to ask local college students to help them with their research.